NEO Key Statistics, Chart & Performance
The current stock price of NEO is 12.3 USD. In the past month the price increased by 1.65%. In the past year, price decreased by -27.56%.
NEO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.68 | 101.58B | ||
| CI | THE CIGNA GROUP | 9.72 | 73.73B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 125.15 | 23.02B | ||
| LH | LABCORP HOLDINGS INC | 15.99 | 20.97B | ||
| DGX | QUEST DIAGNOSTICS INC | 17.98 | 19.52B | ||
| GH | GUARDANT HEALTH INC | N/A | 13.06B | ||
| DVA | DAVITA INC | 12.3 | 8.01B | ||
| HIMS | HIMS & HERS HEALTH INC | 63.15 | 7.76B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 37.1 | 6.82B | ||
| CHE | CHEMED CORP | 19.75 | 6.15B | ||
| RDNT | RADNET INC | 191.61 | 5.62B | ||
| OPCH | OPTION CARE HEALTH INC | 21.6 | 5.11B |
Related stock screener links
About NEO
Company Profile
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,200 full-time employees. The company went IPO on 2012-12-10. The firm offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. The company operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
Company Info
NEOGENOMICS INC
9490 Neogenomics Way
Fort Myers FLORIDA 33913 US
CEO: Douglas M. VanOort
Employees: 2200
Phone: 12397680600
NEOGENOMICS INC / NEO FAQ
What does NEO do?
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,200 full-time employees. The company went IPO on 2012-12-10. The firm offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. The company operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
What is the stock price of NEOGENOMICS INC today?
The current stock price of NEO is 12.3 USD. The price increased by 0.16% in the last trading session.
Does NEOGENOMICS INC pay dividends?
NEO does not pay a dividend.
What is the ChartMill technical and fundamental rating of NEO stock?
NEO has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for NEO stock?
The Revenue of NEOGENOMICS INC (NEO) is expected to grow by 9.55% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is NEOGENOMICS INC worth?
NEOGENOMICS INC (NEO) has a market capitalization of 1.59B USD. This makes NEO a Small Cap stock.
NEO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to NEO. When comparing the yearly performance of all stocks, NEO turns out to be only a medium performer in the overall market: it outperformed 55.71% of all stocks.
NEO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NEO. The financial health of NEO is average, but there are quite some concerns on its profitability.
NEO Financial Highlights
Over the last trailing twelve months NEO reported a non-GAAP Earnings per Share(EPS) of 0.1. The EPS increased by 11.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.25% | ||
| ROE | -13.54% | ||
| Debt/Equity | 0.41 |
NEO Forecast & Estimates
19 analysts have analysed NEO and the average price target is 13.03 USD. This implies a price increase of 5.96% is expected in the next year compared to the current price of 12.3.
For the next year, analysts expect an EPS growth of -12.21% and a revenue growth 9.55% for NEO